Tildrakizumab: Phase III data

Top-line data from the double-blind Phase III MK-3222-010 trial in about 772 patients with moderate to severe plaque psoriasis showed that 100

Read the full 224 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE